Search | Clinical Trials Finder

Conditions: Healthy
Interventions: Tripelennamine, Diphenhydramine, Vehicle Control Cream Base; Drug
Lead sponsor: Palm Beach Atlantic University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Primary Open Angle Glaucoma
Interventions: Canaloplasty using the iTrack microcatheter with Healon GV Pro, Canaloplasty using the Omni surgical system with Healon GV Pro, Canaloplasty using the iTrack microcatheter with Healon Pro, Canaloplasty using the Omni surgical system with Healon Pro; Device
Lead sponsor: Nova Eye, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Glendale, Arizona • Beverly Hills, California • Orange, California + 4 more

Conditions: Hepatitis C, Chronic
Interventions: Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 64 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glaucoma
Interventions: XEN-45 Gel Stent, Trabeculectomy; Device · Procedure
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 35
States / cities: Fayetteville, Arkansas • Arcadia, California • Culver City, California + 31 more

Conditions: Cataract
Interventions: DisCoVisc®, Healon, Amvisc Plus; Device · Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 49 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Patients With Moderate to Severe Perioral Lines
Interventions: JUVEDERM® Ultra XC, Belotero Balance®; Device
Lead sponsor: Allergan; Industry
Eligibility: 35 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Central Nervous System Sarcoma, Ependymoma, Glioma, Malignant Intracranial Germ Cell Tumor, Medulloblastoma, Pineoblastoma, Primary Central Nervous System Neoplasm
Interventions: Placebo Administration, Questionnaire Administration, Wound Dressing Material; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acne Vulgaris
Interventions: Clindamycin and benzoyl peroxide gel (Duac® Topical Gel), benzoyl peroxide and adapalene gel (EPIDUO™ Gel); Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 2
States / cities: Rockville, Maryland • Warren, Michigan

Conditions: Chondromalacia Patella, Patellofemoral Pain Syndrome
Interventions: Synvisc-One™, Sham Treatment; Device · Other
Lead sponsor: University of Virginia; Other
Eligibility: 15 Years to 45 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hypogonadal Males
Interventions: Testosterone Gel (FE 999303); Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Garden City, New York

Conditions: Cataract
Interventions: CVisc50 OVD, ProVisc OVD, Cataract Surgery; Device · Procedure
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 45 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 22
States / cities: Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 18 more

Conditions: Acne
Interventions: Doxycycline Anhydrous 40 MG, Adapalene/Benzoyl Peroxide Gel 0.3-2.5%; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Genitourinary Syndrome of Menopause (GSM)
Interventions: Revaree, Estrace; Device · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Radiation Dermatitis
Interventions: RadiaPlexRx Gel, Aquaphor Gel; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Venous Disease, Venous Vascular Diseases and Syndromes, Venous Insufficiency, Venous Ulcers
Interventions: Cryotherapy: Cooling gel wrap, Usual care; Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Charleston, South Carolina • Spartanburg, South Carolina

Conditions: Intrinsic Aging of Skin
Interventions: Juvéderm Ultra, Cosmoderm 1; Device
Lead sponsor: Steven Fagien; Other
Eligibility: 25 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Urinary Incontinence, Urinary Incontinence (UI), Urinary Incontinence , Stress, Urinary Incontinence Due to Urethral Sphincter Incompetence, Urethral Sphincter Activity, Intrinsic Sphincter Deficiency, Pelvic Floor Dysfunction
Interventions: NASHA Dx, Bulkamid; Device
Lead sponsor: Palette Life Sciences, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Tustin, California • Lincoln, Nebraska • Charlotte, North Carolina + 2 more

Conditions: Degenerative Disc Disease
Interventions: IDCT, Saline Solution, Sodium Hyaluronate; Biological · Drug
Lead sponsor: DiscGenics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more

Conditions: Cataracts
Interventions: DisCoVisc, DuoVisc, BioVisc, Healon5, Amvisc Plus; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 49 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: HIV Prevention
Interventions: DuoGel; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Surgery
Interventions: TEG 6s Citrated K, KH, RTH, FFH Cartridge, Clauss Fibrinogen; Diagnostic Test
Lead sponsor: Haemonetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • New Orleans, Louisiana + 4 more

Conditions: Anesthesia, Local
Interventions: LET Gel after STAR Particle Application (Right or Left Arm), LET Gel Application without STAR Particle Application (Contralateral Arm); Device · Other
Lead sponsor: Emory University; Other
Eligibility: 10 Years to 21 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Bacterial Vaginosis
Interventions: Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel; Drug
Lead sponsor: Starpharma Pty Ltd; Industry
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 32 more

Conditions: Bacterial Vaginosis
Interventions: DARE-BV1clindamycin phosphate vaginal gel, 2%; Drug
Lead sponsor: Daré Bioscience, Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 10
States / cities: Tucson, Arizona • Denver, Colorado • Miami, Florida + 6 more

Search by objective public record fields.

Topical Tripelennamine 1% Cream Versus Diphenhydramine 1% Cream for the Relief of Histamine-Induced Itching: A Proof Concept Study in Healthy Adults.

Multicenter Ab-interno Glaucoma Study Investigating Canaloplasty

The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study

XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS)

To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.

JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines

StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord

A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne

Randomized Evaluation of the Efficacy of Synvisc-One® for the Treatment of Patellofemoral Chondromalacia

A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator

A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50

The Use of Oracea and Epiduo Forte in Severe Acne Patients

A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause

Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients

Cooling Lower Leg Skin to Prevent Venous Leg Ulcers in Patients With Poor Vein Circulation

Comparative Study of Reconstituted JUVÉDERM® Ultra vs COSMODERM® 1 for Lip and Cheek Lines, Folds or Wrinkles

Trial of NASHA Dx Urethral Bulking System

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

DisCoVisc Comparative Evaluation

ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study

An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge

Lidocaine Administration Using STAR Particles

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)